Document:

EX-10.1

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

Exhibit 10.1 
 PURCHASE
AGREEMENT – KIT PURCHASES 
  
 This
Purchase Agreement between diaDexus, Inc. located at 349 Oyster Point Blvd, South San Francisco, CA 94080 (“diaDexus”) and Health Diagnostics Laboratory located at 737 N. 5th Street, Richmond, VA 23219 and any or all of its subsidiaries or
affiliates (“Lab”), sets forth the terms and conditions upon which diaDexus will sell to Lab, and Lab will purchase, various products (the “Agreement”). 

As of October 18, 2013 (“Effective Date”) the parties agree as follows: 

 

	A.	In consideration of the terms and conditions herein and Lab purchasing from diaDexus products specified in the current diaDexus published Product Catalog and US Price List (“Products”) diaDexus
agrees to sell the Products listed in the price section of Exhibit A to Lab at prices set forth therein. Discounts for Products apply only to those Products for which a discount is listed in Exhibit A. Lab shall use Products solely for performing in
vitro clinical diagnostic testing on human blood samples for the purpose of patient clinical management (“Permitted Use”). Lab shall not sell, offer to sell, distribute or transfer Products to other entities. 

Any discount received by Lab hereunder is a “discount or other reduction in price” under Section 1128B(b)(3)(A) of the Social
Security Act. diaDexus shall indicate any such discount on the relevant invoice or by other means that reasonably identifies the discount provided to Lab. Lab shall accurately disclose all discounts received by it to any federal or state health care
program which provides reimbursement for the kits and to any regulatory body having oversight over such health care program, as required by 42 C.F.R. § 1001.952(h) and as otherwise required by applicable law. 

 

	B.	The term of the Agreement shall commence on the Effective Date and expire on June 30, 2015 (the “Term”). The parties hereto acknowledge that this Agreement, including any exhibits and addendums attached
hereto, sets forth the entire agreement and understanding of the parties as to the subject matter hereof, and supersedes all prior and contemporaneous discussions, agreements, and writings with respect hereto with respect to the subject matter
hereof. All previous agreements between diaDexus and Lab and Lab’s subsidiaries will terminate and be null and void effective as of the Effective Date of this Agreement. This Agreement may not be amended or modified except by written agreement
of both of the parties. This Agreement may be terminated by either party with or without cause at any time with ninety (90) days written notice. 

All obligations pursuant to the terms and conditions of Paragraphs D, E, F, G, H, I, J, K, M and O shall survive expiration or termination
of this Agreement and continue in full force and effect for a period of five (5) years after the effective date of such expiration or such termination. 
  

	C.	diaDexus shall ship Product(s) to the Lab which orders such Product(s) under a purchase order and which is authorized by the parties under this Agreement. Shipment shall be made FOB diaDexus’ supply source.
diaDexus shall have no obligation to accept return of Product(s) or replace any shipment of Product(s) after delivery of such shipment of Product(s) by diaDexus. Products shall be supplied in accordance with a specification for identity and quality
of the Product as set forth in the product insert (the “Specification”). The Specifications are considered a performance guaranty and represent the expectation for the Product’s performance by Lab. Unless otherwise specified in the
purchase order, diaDexus shall ship Product to the following address: 

 Health Diagnostics Laboratory 

Receiving Department 
 737 N.
5th Street 
 Richmond, VA 23219 

Phone: 804.343.2718 
  

	D.	[ * ] prior to [ * ], Lab shall provide diaDexus with [ * ]. Lab shall provide diaDexus with [ * ]. Lab shall provide diaDexus with
[ * ] during the Term. No later than [ * ] Lab shall provide [ * ]. Such [ * ] shall [ * ]. 

 

	E.	Lab shall pay diaDexus net thirty (30) days after the date stated on invoice provided by diaDexus to Lab. All applicable taxes are the responsibility of Lab. In those states where diaDexus collects local/state
sales taxes, diaDexus will add these taxes to the invoices and after receipt of payment including such taxes from Lab, remit to the appropriate taxing authority. Any payment due and payable under the terms and conditions of this Agreement made after
the date such payment is due and payable shall bear interest as of the day after the date such payment was due and payable and shall continue to accrue such interest until such payment is made at a rate equal to the lesser of the prime rate as
reported by JPMorgan Chase & Co., New York, New York, on the date such payment is due, plus an additional two percent (2%), or the maximum rate permitted by law if lower. All payments made under this Agreement shall be made in U.S. dollars,
and such payments shall be made by check or wire transfer to one or more bank accounts to be designated in writing by diaDexus. Notwithstanding anything to the contrary, diaDexus shall have no obligation to continue delivering Product pursuant to
the terms of this Agreement in the event that Lab fails to make any payment due and payable pursuant to this Agreement. 

  
 Page 1 of 4 

 

	F.	Invoices, notices and other communications permitted or required under this Agreement will be deemed to be properly given if in writing and either delivered by hand or mailed by First Class U.S. Mail, postage prepaid,
addressed to the applicable party as follows: 

  

			
	 Health Diagnostics Laboratory
 737 N. 5th
Street
 Richmond, VA 23219
 Attention: Tonya Mallory
	  	 diaDexus, Inc.
 349 Oyster Point
Boulevard
 South San Francisco, CA 94080
 Attention:
CEO

  

	G.	Lab shall label Product on its test requisition order forms as set forth in the current diaDexus published Product Catalog and US Price List (e.g.
PLAC® Test for Lp-PLA2). If Lab wishes to market the diaDexus Product using the associated marks, diaDexus hereby grants to Lab a
non-exclusive, non-sublicensable license to use its trademarks solely for the Permitted Use. Under such license, Lab shall comply with diaDexus policy regarding use of diaDexus marks. Lab shall submit all proposed representations of any trademarks
to diaDexus for approval in writing, such approval shall not be unreasonably withheld or delayed. Except as expressly set forth in this Paragraph G, nothing in this Agreement shall be deemed to grant or assign to Lab any rights under any patents,
patent applications, trade secrets, trademarks, copyrights or other proprietary intellectual property rights of diaDexus. 

  

	H.	The parties have provided to each other prior to entering into this Agreement, and in connection with this Agreement may in the future provide to each other, confidential information, including but not limited to each
party’s know-how, inventions, improvements, discoveries, patent applications, trade secrets, devices, compositions, formulas, ideas, designs, drawings, specifications, techniques, data, computer programs, processes, customer lists, product
prices, discounts, sales data, marketing, product development and other business plans, legal affairs and financial and technical information and material embodiments thereof (“Confidential Information”). 

Confidential Information may be disclosed orally or in writing. Each receiving party may disclose this Confidential Information only to its
employees, agents and consultants on a need to know basis; provided that any such person to whom disclosure is made is bound by obligations of non-disclosure and non-use no less restrictive than those set forth herein. The receiving party
shall take the same degree of care that such party uses to protect its own confidential and proprietary information of a similar nature and importance, but in no event shall such care be less than reasonable care. The receiving party shall not
disclose such Confidential Information to any third party, and shall not use such Confidential Information for any purpose except as expressly permitted under the terms and conditions of this Agreement. This obligation of confidentiality shall not
apply to any information that (a) is in the public domain, (b) comes into the public domain through no fault of the receiving party, (c) is disclosed to the receiving party by a third party having a lawful right to make such
disclosure, (d) is in response to a valid order of a court or other governmental body or (e) is required by law or regulation; provided, however, that the receiving party shall first have given reasonable prior notice to the
disclosing party and shall have made a reasonable effort to obtain a protective order, or to cooperate with the disclosing party’s efforts, as applicable, to obtain a protective order limiting the extent of such disclosure and requiring that
the Confidential Information so disclosed be used only for the purposes for which such order was issued or as required by such law or regulation. The terms and conditions of this Agreement shall be Confidential Information of the parties. 

 

	I.	diaDexus represents and warrants to Lab that the Products supplied shall (i) not be adulterated or misbranded by diaDexus within the meaning of the U.S. Food, Drug, and Cosmetic Act; and (ii) function in
accordance with the documentation supplied by diaDexus in connection with such Products after delivery to Lab in accordance with Paragraph C; provided that Lab maintains and stores such Products in accordance with instructions contained in
such documentation. EXCEPT AS SPECIFICALLY SET FORTH IN THIS PARAGRAPH I, DIADEXUS MAKES NO REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, ANY WARRANTY OF FITNESS FOR A
PARTICULAR PURPOSE OR USE, ANY WARRANTY OF NON-INFRINGEMENT, ANY WARRANTY OF SAFETY, OR ANY OTHER STATUTORY WARRANTY. 

  

	J.	diaDexus’s liability to Lab shall not exceed the aggregate amount (if any) received by diaDexus in exchange for the Products during the Term. EXCEPT IN CONNECTION WITH THE PARTIES’ OBLIGATIONS UNDER PARAGRAPH
H, IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL, INDIRECT, PUNITIVE, EXEMPLARY, OR SPECIAL DAMAGES INCURRED BY THE OTHER OR ANY AFFILIATE OR SUBSIDIARY ARISING OUT OF OR RELATED TO THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY
THEORY OF LIABILITY. 

  

	K.	diaDexus acknowledges that Lab has a proprietary interest in its legal and business name and reputation. Lab acknowledges that diaDexus has a proprietary interest in its legal and business name and reputation as well as
the brand name and trademarks of its products. Therefore, each party agrees that it shall not use the other party’s name nor shall a party mention or describe this Agreement or its relationship with the other party in any press release,
advertising, marketing, and promotional materials or other publications or materials without first obtaining the prior written approval of the other party. 

  

	L.	diaDexus will not be liable for any failure to perform under this Agreement due to strikes, fire, explosion, flood, riot, lock-out, injunction, interruption of transportation, unavoidable accidents, or inability to
obtain supplies at reasonable prices. In the event that a Product is unavailable, diaDexus will notify Lab of such unavailability by written or electronic communication, and diaDexus will, within the course of twenty-one (21) working days,
notify Lab of an action plan to correct the problem. 

  
 Page 2 of 4 

 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

	M.	If any term, condition or provision of this Agreement is held to be unenforceable for any reason, it shall be interpreted to achieve the intent of the parties to this Agreement to the extent possible rather than voided.
In any event, all other terms, conditions, and provisions of this Agreement shall be deemed valid and enforceable to the full extent. 

  

	N.	Each party shall carry out its activities pursuant to this Agreement in compliance with all applicable federal, state, and local laws, rules, regulations, and guidelines. 

 

	O.	In accordance with Federal and State “Sunshine Acts” diaDexus collects and reports information relating to transfers of value to healthcare professionals. As such, Lab is required to provide the following
information for each healthcare professional that may receive payment or transfer of value from this Agreement: 

 Name: 

Address: 
 National Provider
Identification: 
 State of Medical License & Number: 
  

	P.	This Agreement shall be governed by and interpreted in accordance with the laws of the State of California, excluding conflicts of laws principles. 

 

	Q.	Except as expressly provided herein, neither this Agreement nor any interest hereunder will be assignable, nor any other obligation delegable, by a party without the prior written consent of the other; provided,
however, diaDexus may assign this Agreement without consent to any successor in interest by way of merger or sale of all or substantially all of its assets in a manner such that the assignor will remain liable and responsible for the performance and
observance of all such duties and obligations hereunder. Any purported assignments made in violation of this Paragraph Q shall be null and void. 

  

	R.	To the extent that there is any conflict or inconsistency between this Agreement and any purchase order, the current diaDexus published Product Catalog and US Price List, or any other document pertaining
to the supply of Product, the terms of this Agreement shall govern unless specifically acknowledged and agreed to in writing by each of the parties. This Agreement, including without limitation all Exhibits, contain the entire agreement among the
parties relating to the subject matter herein and all prior proposals, discussions and writings by and among the parties and relating to the subject matter herein, whether written or oral, are superseded hereby and thereby. None of the terms of this
Agreement shall be deemed to be amended unless such amendment is in writing, signed by all parties hereto, and recites specifically that it is an amendment to the terms of this Agreement. 

 

			
	Health Diagnostics Laboratory	  	diaDexus, Inc.
		
	 By: /s/ Tonya Mallory
	  	 By: /s/ Brian Ward

		
	 Name: Tonya Mallory
	  	 Name: Brian Ward

		
	 Title: President & CEO
	  	 Title: President & CEO

		
	 Date: 10/15/13
	  	 Date: 10/16/13

  
 Page 3 of 4 

 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

 Exhibit A 

Price 
 diaDexus agrees to sell the individual Products
listed in Table 1 to Lab at prices based on a current published list price less a limited term discount as set forth in Table 1 below. 
 Table 1. Individual
Product Discount Table 
  

							
	 	 	[ * ]	  	Discount from list price	  	[ * ]%
	 	(PLAC® Test ELISA)	  	Effective price	  	$ [ * ]

  
 Page 4 of 4 

 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.EX-10.1

 Exhibit 10.1 
  

			
	

	  	Note Modification Agreement

 This agreement is dated as of August 15, 2013 (the “Agreement Date”), by and between TASER
International, Inc. (the “Borrower”) and JPMorgan Chase Bank, N.A. (together with its successors and assigns, the “Bank”). The provisions of this agreement are effective on the date that this agreement has been
executed by all of the signers and delivered to the Bank (the “Effective Date”). 
 WHEREAS, the Borrower executed a Line of Credit
Note dated as of June 4, 2010 in the original principal amount of Ten Million and 00/100 Dollars ($10,000,000.00), (as same may have been amended or modified from time to time, the “Note”) as evidence of an extension of credit
from the Bank to the Borrower, which Note has at all times been, and is now, continuously and without interruption outstanding in favor of the Bank; and, 

WHEREAS, the Borrower has requested and the Bank has agreed that the Note be modified to the limited extent as hereinafter set forth in this agreement;

 NOW THEREFORE, in mutual consideration of the agreements contained herein and for other good and valuable consideration, the parties agree as
follows: 
 1. ACCURACY OF RECITALS. The Borrower acknowledges the accuracy of the Recitals stated above. 

2. DEFINITIONS. Capitalized terms used in this agreement shall have the same meanings as in the Note, unless otherwise defined in this agreement. 

3. MODIFICATION OF NOTE. 
 3.1 From and
after the Effective Date, the provision in the Note captioned “Promise to Pay” is hereby amended as follows: The date on which the entire balance of unpaid principal plus accrued interest shall be due and payable immediately is
hereby changed from July 31, 2014 to July 31, 2015. 
 3.2 From and after the Effective Date, the provision in the Note captioned
“Principal Payments.” is hereby amended to read as follows: Principal Payments. All outstanding principal and interest is due and payable in full on July 31, 2015, which is defined herein as the “Principal Payment Date”.

 3.3 Each of the Related Documents is modified to provide that it shall be a default or an event of default thereunder if the Borrower
shall fail to comply with any of the covenants of the Borrower herein or if any representation or warranty by the Borrower herein or by any guarantor in any Related Documents is materially incomplete, incorrect, or misleading as of the date hereof.
As used in this agreement, the “Related Documents” shall include the Note and all applications for letters of credit, loan agreements, credit agreements, reimbursement agreements, security agreements, mortgages, deeds of trust,
pledge agreements, assignments, guaranties, or any other instrument or document executed in connection with the Note or in connection with any other obligations of the Borrower to the Bank. 

3.4 Each reference in the Related Documents to any of the Related Documents shall be a reference to such document as modified by this
agreement. 
 4. RATIFICATION OF RELATED DOCUMENTS AND COLLATERAL. The Related Documents are ratified and reaffirmed by the Borrower and shall remain
in full force and effect as they may be modified by this agreement. All property described as security in the Related Documents shall remain as security for the Note, as modified by this agreement, and the Liabilities under the other Related
Documents. 
 5. BORROWER REPRESENTATIONS AND WARRANTIES. The Borrower represents and warrants to the Bank that each of the representations and
warranties made in the Note and the other Related Documents and each of the following representations and warranties are and will remain, true and correct until the later of maturity or the date on which all Liabilities evidenced by the Note are
paid in full: 
 5.1 No default, event of default or event that would constitute a default or event of default but for the giving of notice,
the lapse of time or both, has occurred and is continuing under any provision of the Note, as modified by this agreement, or any other Related Document. 

5.2 No event has occurred which may in any one case or in the aggregate materially and adversely affect the financial condition, properties,
business, affairs, prospects or operations of the Borrower or any guarantor or any subsidiary of the Borrower. 

 5.3 The Borrower has no defenses or counterclaims, offsets or adverse claims, demands or actions
of any kind, personal or otherwise, that it could assert with respect to the Note or any other Liabilities. 
 5.4 The Note, as modified by
this agreement, and the other Related Documents are the legal, valid, and binding obligations of the Borrower and the other parties, enforceable against the Borrower and other parties in accordance with their terms, except as may be limited by
bankruptcy, insolvency or other laws affecting the enforcement of creditors’ rights generally and by general principles of equity. 

5.5 The Borrower, other than any Borrower who is a natural person, is validly existing under the laws of the State of its formation or
organization. The Borrower has the requisite power and authority to execute and deliver this agreement and to perform the obligations described in the Related Documents as modified herein. The execution and delivery of this agreement and the
performance of the obligations described in the Related Documents as modified herein have been duly authorized by all requisite action by or on behalf of the Borrower. This agreement has been duly executed and delivered by or on behalf of the
Borrower. 
 6. BORROWER COVENANTS. The Borrower covenants with the Bank: 

6.1 The Borrower shall execute, deliver, and provide to the Bank such additional agreements, documents, and instruments as reasonably required
by the Bank to effectuate the intent of this agreement. 
 6.2 The Borrower fully, finally, and forever releases and discharges the Bank, its
successors, and assigns and their respective directors, officers, employees, agents, and representatives (each a “Bank Party”) from any and all causes of action, claims, debts, demands, and liabilities, of whatever kind or nature,
in law or equity, of the Borrower, whether now known or unknown to the Borrower, (i) in respect of the loan evidenced by the Note and the Related Documents, or of the actions or omissions of any Bank Party in any manner related to the loan
evidenced by the Note or the Related Documents and (ii) arising from events occurring prior to the date of this agreement. 
 6.3 To the
extent not prohibited by applicable law, the Borrower shall pay to the Bank: 
 6.3.1 All the internal and external costs and expenses
incurred (or charged by internal allocation) by the Bank in connection with this agreement (including, without limitation, inside and outside attorneys, appraisal, appraisal review, processing, title, filing, and recording costs, expenses, and
fees). 
 7. EXECUTION AND DELIVERY OF AGREEMENT BY THE BANK. The Bank shall not be bound by this agreement until (i) the Bank has executed this
agreement and (ii) the Borrower has executed and delivered this agreement together with all other related documents requested by the Bank, and the Borrower has fully satisfied all other conditions precedent, as determined by the Bank in its
sole discretion. 
 8. INTEGRATION, ENTIRE AGREEMENT, CHANGE, DISCHARGE, TERMINATION, OR WAIVER. The Note, as modified by this agreement, and the
other Related Documents contain the complete understanding and agreement of the Borrower and the Bank in respect of any Liabilities evidenced by the Note and supersede all prior understandings, and negotiations. If any one or more of the obligations
of the Borrower under this agreement or the Note, as modified by this Agreement, is invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining obligations of the Borrower shall not in any way be
affected or impaired, and the invalidity, illegality or unenforceability in one jurisdiction shall not affect the validity, legality or enforceability of the obligations of the Borrower under this agreement, the Note as modified by this agreement
and the other Related Documents in any other jurisdiction. No provision of the Note, as modified by this agreement, or any other Related Documents may be changed, discharged, supplemented, terminated, or waived except in a writing signed by the
party against whom it is being enforced. 
 9. GOVERNING LAW AND VENUE. This agreement shall be governed by and construed in accordance with the laws
of the State of Arizona (without giving effect to its laws of conflicts). The Borrower agrees that any legal action or proceeding with respect to any of its obligations under the Note or this agreement may be brought by the Bank in any state or
federal court located in the State of Arizona, as the Bank in its sole discretion may elect. By the execution and delivery of this agreement, the Borrower submits to and accepts, for itself and in respect of its property, generally and
unconditionally, the non-exclusive jurisdiction of those courts. The Borrower waives any claim that the State of Arizona is not a convenient forum or the proper venue for any such suit, action or proceeding. This agreement binds the Borrower and its
successors, and benefits the Bank, its successors and assigns. The Borrower shall not, however, have the right to assign the Borrower’s rights under this agreement or any interest therein, without the prior written consent of the Bank. 

10. COUNTERPART EXECUTION. This agreement may be executed in multiple counterparts, each of which, when so executed, shall be deemed an original, but
all such counterparts, taken together, shall constitute one and the same agreement. 

  
 2 

 11. NOT A NOVATION. This agreement is a modification only and not a novation. In addition to all amounts
hereafter due under the Note, as modified by this agreement, and the other Related Documents, all accrued interest evidenced by the Note being modified by this agreement and all accrued amounts due and payable under the Related Documents shall
continue to be due and payable until paid. Except for the modification(s) set forth in this agreement, the Note, the other Related Documents and all the terms and conditions thereof, shall be and remain in full force and effect with the changes
herein deemed to be incorporated therein. This agreement is to be considered attached to the Note and made a part thereof. This agreement shall not release or affect the liability of any guarantor, surety or endorser of the Note or release any owner
of collateral securing the Note. The validity, priority and enforceability of the Note shall not be impaired hereby. References to the Related Documents and to other agreements shall not affect or impair the absolute and unconditional obligation of
the Borrower to pay the principal and interest on the Note when due. The Bank reserves all rights against all parties to the Note and the other Related Documents. 

12. TIME IS OF THE ESSENCE. Time is of the essence under this agreement and in the performance of every term, covenant and obligation contained
herein. 
  

													
		  		  		  	Borrower:	  
				
	Address:	  	 17800 N 85TH Street
 Scottsdale, AZ
85260-1627
	  		  	TASER International, Inc.	  
		  		  		  	By:	  	 /s/ Daniel M. Behrendt
	   

						
		  		  		  		  	                Daniel M. Behrendt	 	 	  CFO	  
		  		  		  		  	 Printed
 Name
	 	 	  Title	  
				
		  		  		  	Date Signed: October 21, 2013	  

 BANK’S ACCEPTANCE 

The foregoing agreement is hereby agreed to and acknowledged. 
  

					
	Bank:
	
	 JPMorgan Chase Bank, N.A

		
	By:	 	 /s/ Hana Deiter

		
		 	 Hana Deiter
                SVP JP Morgan Chase Bank

		 	Printed Name	 	Title
	
	Date Signed: October 21, 2013

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]